Related Experiment Video
Updated: Feb 27, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
The obstetric experience of women with factor XI deficiency
Claudia Chi1, Ashwini Kulkarni, Christine A Lee
1Department of Obstetrics and Gynaecology, Royal Free Hospital, London, UK.
OBJECTIVES. To assess the obstetric outcome in women with factor XI (FXI) deficiency. DESIGN. Retrospective review of medical records. SETTING. Tertiary referral university hospital. POPULATION. Women with FXI deficiency. METHOD. Review of pregnancies over a 10-year period (1997-2006). Main outcome measures. Pregnancy outcome, mode of delivery, changes in FXI levels during pregnancy, use of prophylaxis during labor and delivery, antepartum hemorrhage, and postpartum hemorrhage (PPH). RESULTS. There were 61 pregnancies among 30 women with FXI deficiency (two severe, FXI level <15-20 IU/dL, and 28 partial, FXI level 20-70 IU/dL) resulting in 49 live births (two sets of twins), eight miscarriages, and six terminations of pregnancy. The modes of delivery included 38 spontaneous vaginal deliveries, three instrumental deliveries, and six cesarean sections (two emergency and four elective). No significant change in FXI levels was observed during pregnancy. Intrapartum prophylaxis with FXI concentrate or tranexamic acid was given in 19 deliveries where the mother had a positive bleeding history. Four women had excessive bleeding related to pregnancy loss and three experienced antepartum bleeding. All these women had a positive bleeding history. There were five (11%) primary and five (11%) secondary PPHs among seven women including four with a positive bleeding history. CONCLUSION. Women with FXI deficiency, particularly those with a positive bleeding history, are at risk of bleeding complications related to miscarriage or childbirth. The unpredictable nature of their bleeding tendency demands careful planning and close collaborations between obstetricians and hematologists.
OBJECTIVES. To assess the obstetric outcome in women with factor XI (FXI) deficiency. DESIGN. Retrospective review of medical records. SETTING. Tertiary referral university hospital. POPULATION. Women with FXI deficiency. METHOD. Review of pregnancies over a 10-year period (1997-2006). Main outcome measures. Pregnancy outcome, mode of delivery, changes in FXI levels during pregnancy, use of prophylaxis during labor and delivery, antepartum hemorrhage, and postpartum hemorrhage (PPH). RESULTS. There were 61 pregnancies among 30 women with FXI deficiency (two severe, FXI level <15-20 IU/dL, and 28 partial, FXI level 20-70 IU/dL) resulting in 49 live births (two sets of twins), eight miscarriages, and six terminations of pregnancy. The modes of delivery included 38 spontaneous vaginal deliveries, three instrumental deliveries, and six cesarean sections (two emergency and four elective). No significant change in FXI levels was observed during pregnancy. Intrapartum prophylaxis with FXI concentrate or tranexamic acid was given in 19 deliveries where the mother had a positive bleeding history. Four women had excessive bleeding related to pregnancy loss and three experienced antepartum bleeding. All these women had a positive bleeding history. There were five (11%) primary and five (11%) secondary PPHs among seven women including four with a positive bleeding history. CONCLUSION. Women with FXI deficiency, particularly those with a positive bleeding history, are at risk of bleeding complications related to miscarriage or childbirth. The unpredictable nature of their bleeding tendency demands careful planning and close collaborations between obstetricians and hematologists.
Related Concept Videos
Venous Thrombosis IV: Nursing Management
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...

